"Cancersensor": Circadian Rhythms

Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : the Circadian Rhythms of Urinary Excretion of Modified Nucleosides.

NCT01693835•Institut National de la Santé Et de la Recherche Médicale, France

View on ClinicalTrials.gov

Summary

Observational, non randomized study aimed at measuring the circadian rhythms in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer and in 30 age and sex-matched healthy subjects.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Histologically-confirmed metastatic colorectal cancer;
•0 to 3 prior chemotherapy lines;
•Signed informed consent;
•Good understanding of the protocol and of the follow-up;
•Estimated life expectancy exceeding 3 months;
•At least one measurable metastatic lesion (RECIST criteria);
•Performance Status (WHO) of 0 to 2;
•Good haematological, hepatic and renal functions.
•Age ≥ 18 ans
•Signed informed consent;
+4 more criteria

Exclusion Criteria

•Poor performance status (\>2);
•Poor haematological, hepatic or renal functions;
•Uncontrolled chronic disease;
•Serious unhealed wound, ulcer or fracture within the previous month;
•Clinical or laboratory finding suggesting possible abnormalities in nucleosides urinary excretion;
•Pregnancy or breast-feeding during the previous month;
•Transmeridian trip of more than 4 time zones within the prior 2 weeks;
•Person with legal restriction to participate into clinical research, according to the current law in France.
•Poor haematological, hepatic or renal functions;
•Uncontrolled chronic disease;
+5 more criteria

Locations (1)

Paul Brousse Hospital

Villejuif, France

Key Dates

Start Date

August 1, 2012

Primary Completion Date

June 1, 2014

Completion Date

June 1, 2014

Last Updated

November 18, 2025

Enrollment

ACTUAL participants

Conditions

Metastatic Colorectal Cancer

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Advanced CancerMetastatic Cancer+7 more

View study

RECRUITINGPHASE1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

Solid Tumor, AdultMetastatic Breast Cancer+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

"Cancersensor": Circadian Rhythms

Inclusion Criteria

Exclusion Criteria

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer